Finance

Lists
BAX:NYSE
Baxter International Inc
26,95 US$
-2,39%
(-0,66) 1D
26,95 US$
0,00% (0,00)
After hours
Closed: 12 აგვ, 16:00:07 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for BAX...
Open
27,20 US$
High
27,40 US$
Low
26,64 US$
Mkt. cap
13,93 მლრდ.
Avg. vol.
7,16 მლნ.
Volume
6,88 მლნ.
Dividend
0,15%
Quarterly dividend
0,01 US$
Ex-dividend date
28 აგვ. 2026
52-wk high
30,00 US$
52-wk low
15,73 US$
EPS
-2,07 US$
Beta
0,60
Shares outstanding
517,00 მლნ.
No. of employees
38 ათ.
Open
27,20 US$
High
27,40 US$
Low
26,64 US$
Mkt. cap
13,93 მლრდ.
Avg. vol.
7,16 მლნ.
Volume
6,88 მლნ.
Dividend
0,15%
Quarterly dividend
0,01 US$
Ex-dividend date
28 აგვ. 2026
52-wk high
30,00 US$
52-wk low
15,73 US$
EPS
-2,07 US$
Beta
0,60
Shares outstanding
517,00 მლნ.
No. of employees
38 ათ.
News stories
From web sources and news partners
Profile
Baxter International Inc. is an American multinational healthcare company with headquarters in Deerfield, Illinois. The company primarily focuses on products to treat chronic and acute medical conditions. The company had 2023 global net sales of $14.8 billion, across three business: "Medical Product and Therapies", "Healthcare Systems and Technologies" and Pharmaceuticals. Baxter's Medical Product and Therapies business comprise two divisions: the first named "Advanced Surgery" that produce technologies to enhance surgeons' technique, increase efficiencies and improve outcomes. The second named "Infusion Therapies and Technologies" produces intravenous products and other products used in the delivery of fluids and drugs to patients. Baxter's Healthcare System and Technologies business has four divisions "Front Line Care", "Digital Platform and Innovations", "Care and Connectivity Solutions" and "Global Services". Baxter's Pharmaceuticals business produce inhalational anaesthetics and other differentiated hospital pharmaceuticals in areas of pain, critical care, anti-infection and oncology. Wikipedia
About Baxter International Inc
CEOენდრიუ ჰიდერ
Employees37,5 ათ.
Founded1931
HeadquartersDeerfield, ილინოისი, ამერიკის შეერთებული შტატები
SectorMedical device
Websitebaxter.com
Analyst ratings
Based on 10 analysts giving stock ratings to BAX in the past 3 months
Hold
Buy
1
Hold
9
Sell
0
12-month forecast
Based on 10 Wall Street analysts offering 12 month price targets for BAX in the last 3 months.
Highest
Current 26,95 US$
29,00 US$ (+7,61%)
Average
25,90 US$ (-3,90%)
Lowest
21,00 US$ (-22,08%)
Analyst
Recommendation
Action
Price target
Projected
Date
Travis Steed
Bank of America Securities
Hold
Maintained
28,00 US$
+3,9%
08/11/2026
Robbie Marcus
J.P. Morgan
Hold
Maintained
26,00 US$
-3,5%
08/06/2026
Pito Chickering
Deutsche Bank
Hold
Maintained
27,00 US$
+0,2%
07/31/2026
Josh Jennings
TD Cowen
Hold
Maintained
29,00 US$
+7,6%
07/31/2026
Unknown Analyst
Wells Fargo
Hold
Reiterated
23,00 US$
-14,7%
07/31/2026
Joanne Wuensch
Citi
Hold
Upgraded
28,00 US$
+3,9%
07/31/2026
Rick Wise
Stifel Nicolaus
Hold
Maintained
28,00 US$
+3,9%
07/31/2026
Danielle Antalffy
UBS
Hold
Reiterated
25,00 US$
-7,2%
07/28/2026
Patrick Wood
UBS
Hold
Reiterated
25,00 US$
-7,2%
07/28/2026
David Roman
Goldman Sachs
Hold
Reiterated
21,00 US$
-22,1%
07/15/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
24,00 US$
-10,9%
07/06/2026
Steven Silver
Argus Research
Hold
Maintained
-
-
05/08/2026
Matt Miksic
Barclays
Buy
Maintained
27,00 US$
+0,2%
05/04/2026
Matthew Taylor
Jefferies
Hold
Reiterated
19,00 US$
-29,5%
02/12/2026
Last report
30 ივლ. 2026
Fiscal period
Q2 2026
EPS / Est. (USD)
0,56 US$ / 0,37 US$
+52,53%beat
Revenue / Est. (USD)
2,96 მლრდ. / 2,80 მლრდ.
+5,88%beat
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
2,84 მლრდ.
2,97 მლრდ.
2,70 მლრდ.
2,96 მლრდ.
Cost of goods sold
1,81 მლრდ.
2,01 მლრდ.
1,80 მლრდ.
1,82 მლრდ.
Cost of revenue
1,81 მლრდ.
2,01 მლრდ.
1,80 მლრდ.
1,82 მლრდ.
Research and development expenses
115,00 მლნ.
116,00 მლნ.
124,00 მლნ.
125,00 მლნ.
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
669,00 მლნ.
675,00 მლნ.
658,00 მლნ.
642,00 მლნ.
Operating expense
734,00 მლნ.
741,00 მლნ.
735,00 მლნ.
715,00 მლნ.
Total operating expenses
2,55 მლრდ.
2,76 მლრდ.
2,54 მლრდ.
2,53 მლრდ.
Operating income
287,00 მლნ.
219,00 მლნ.
163,00 მლნ.
427,00 მლნ.
Other non operating income
2,00 მლნ.
3,00 მლნ.
-1,00 მლნ.
1,00 მლნ.
EBT including unusual items
121,00 მლნ.
-756,00 მლნ.
-6,00 მლნ.
158,00 მლნ.
EBT excluding unusual items
228,00 მლნ.
161,00 მლნ.
93,00 მლნ.
364,00 მლნ.
Income tax expense
172,00 მლნ.
279,00 მლნ.
11,00 მლნ.
23,00 მლნ.
Effective tax rate
142,15%
-36,90%
-183,33%
14,56%
Other operating expenses
-50,00 მლნ.
-50,00 მლნ.
-47,00 მლნ.
-52,00 მლნ.
Net income
-46,00 მლნ.
-1,13 მლრდ.
-15,00 მლნ.
126,00 მლნ.
Net profit margin
-1,62%
-37,93%
-0,56%
4,26%
Earnings per share
0,69
0,44
0,36
0,56
Interest and investment income
10,00 მლნ.
11,00 მლნ.
12,00 მლნ.
13,00 მლნ.
Interest expense
-68,00 მლნ.
-69,00 მლნ.
-78,00 მლნ.
-77,00 მლნ.
Net interest expenses
-58,00 მლნ.
-58,00 მლნ.
-66,00 მლნ.
-64,00 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
524,00 მლნ.
459,00 მლნ.
400,00 მლნ.
666,00 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google აპები